Pharmacokinetic Properties and Human Use Characteristics of an FDA‐Approved Intranasal Naloxone Product for the Treatment of Opioid Overdose
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Parenteral naloxone has been approved to treat opiate overdose for over 4 decades. Intranasal naloxone, administered “off label” using improvised devices, has been widely used by both first responders and the lay public to treat overdose. However, these improvised devices require training for effective use, and the recommended volumes (2 to 4 mL) exceed those considered optimum for intranasal administration. The present study compared the pharmacokinetic properties of intranasal naloxone (2 to 8 mg) delivered in low volumes (0.1 to 0.2 mL) using an Aptar Unit‐Dose device to an approved (0.4 mg) intramuscular dose. A parallel study assessed the ease of use of this device in a simulated overdose situation. All doses of intranasal naloxone resulted in plasma concentrations and areas under the curve greater than those observed following the intramuscular dose; the time to reach maximum plasma concentrations was not different following intranasal and intramuscular administration. Plasma concentrations of naloxone were dose proportional between 2 and 8 mg and independent of whether drug was administered to 1 or both nostrils. In a study using individuals representative of the general population, >90% were able to perform both critical tasks (inserting nozzle into a nostril and pressing plunger) needed to deliver a simulated dose of naloxone without prior training. Based on both pharmacokinetic and human use studies, a 4‐mg dose delivered in a single device (0.1 mL) was selected as the final product. This product can be used by first responders and the lay public, providing an important and potentially life‐saving intervention for victims of an opioid overdose.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increases in drug and opioid overdose deaths — United States, 2000–2014
Rudd, R. A., Aleshire, N., Zibbell, J. E., & Gladden, R. M. (2016) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6450a3 · Cited by 1,859
Saved by the nose: Bystander-administered intranasal naloxone hydrochloride for opioid overdose
Doe-Simkins, M., Walley, A. Y., Epstein, A., & Moyer, P. (2009) · American Journal of Public Health · doi:10.2105/ajph.2008.146647 · Cited by 250
Opioid overdose prevention with intranasal naloxone among people who take methadone
Walley, A. Y., Doe-Simkins, M., Quinn, E., Pierce, C., Xuan, Z., & Ozonoff, A. (2013) · Journal of Substance Abuse Treatment · doi:10.1016/j.jsat.2012.07.004 · Cited by 107
Cited by
Naloxone dosage for opioid reversal: current evidence and clinical implications
Rzasa Lynn, R., & Galinkin, J. (2018) · Therapeutic Advances in Drug Safety · doi:10.1177/2042098617744161 · Cited by 346
The Opioid Epidemic: Crisis and Solutions
Skolnick, P. (2018) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010617-052534 · Cited by 307
Self-citationClinical Pharmacokinetics and Pharmacodynamics of Naloxone
Saari, T. I., Strang, J., & Dale, O. (2024) · Clinical Pharmacokinetics · doi:10.1007/s40262-024-01355-6 · Cited by 77
Dahan, A., Franko, T. S., Carroll, J. W., Craig, D. S., Crow, C., Galinkin, J. L., Garrity, J. C., Peterson, J., & Rausch, D. B. (2024) · Frontiers in Public Health · doi:10.3389/fpubh.2024.1346109 · Cited by 49
Naloxone administration by law enforcement officers in New York State (2015–2020)
Pourtaher, E., Payne, E. R., Fera, N., Rowe, K., Leung, S.-Y. J., Stancliff, S., Hammer, M., Vinehout, J., & Dailey, M. W. (2022) · Harm Reduction Journal · doi:10.1186/s12954-022-00682-w · Cited by 38
Guzman, C. B., Dulude, H., Piché, C., Rufiange, M., Sadoune, A. A., Rampakakis, E., Carballo, D., Triest, M., Zhang, M. X., Zhang, S., et al. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13134 · Cited by 28
“However, drugs that act systemically are also administered nasally,(10) including treatments for migraine (eg, zolmitriptan and sumatriptan),(10) pain (eg, fentanyl)(10,11) and drug overdose (eg, naloxone).(12) Lipophilic drugs are well absorbed from the nasal cavity and often have pharmacokinetic profiles and bioavai…”
Background
Metadata
- Authors
- Krieter, P., Chiang, N., Gyaw, S., Skolnick, P., Crystal, R., Keegan, F., Aker, J., Beck, M., & Harris, J.
- Venue
- The Journal of Clinical Pharmacology
- Publisher
- Wiley
- Published
- 2016-06-10
- Volume
- 56
- Issue
- 10
- Pages
- 1243-1253
- ISSN
- 0021-9754 (ISSN-L)
- 0091-2700
- 1552-4604
- OpenAlex
- W2346610964
- Cited by
- 111
- References
- 3
- FWCI
- 13.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.